```html

Wegener’s Disease (Granulomatosis with Polyangiitis)

Overview

Wegener’s disease, now officially called Granulomatosis with Polyangiitis (GPA), is a rare, systemic autoimmune disorder characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation can lead to necrotizing (tissue‑destroying) granulomas in the respiratory tract and kidneys, producing a triad of classic involvement:

• Upper respiratory tract (sinuses, nose, throat)
• Lower respiratory tract (lungs)
• Kidneys (glomerulonephritis)

GPA can affect any organ system, and the disease course ranges from limited (single‑organ) to severe, life‑threatening multi‑organ disease.

Who it affects: GPA most commonly presents in adults aged 40–60, but it can occur at any age, including childhood. It is slightly more prevalent in men than women (approximately 1.2:1). The disease occurs worldwide, with an estimated incidence of 3–10 cases per million people per year and a prevalence of about 20–30 per million.

Symptoms

Symptoms develop gradually and may fluctuate. Early recognition is essential because organ damage can become irreversible.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, or pressure.
• Nasal crusting or ulceration – may cause nosebleeds (epistaxis).
• Hearing loss – due to eustachian tube dysfunction.
• Sore throat & hoarseness – from granulomatous inflammation of the larynx.

Lower Respiratory Tract

• Cough – often dry, but may become productive with blood-tinged sputum.
• Shortness of breath – especially on exertion.
• Chest pain – pleuritic pain from lung involvement.
• Hemoptysis – coughing up blood, a red‑flag symptom.
• Pulmonary nodules or cavitations seen on imaging.

Kidney Involvement

• Hematuria – blood in the urine, often microscopic.
• Proteinuria – foamy urine.
• Decreased kidney function – fatigue, swelling of ankles/feet, hypertension.

General/Systemic Symptoms

• Fatigue, malaise, and unexplained weight loss.
• Fever and night sweats.
• Arthralgia or arthritis (often in knees, ankles).
• Skin lesions – palpable purpura, ulcerations, or livedo reticularis.
• Eye involvement – conjunctivitis, scleritis, or retinal vasculitis, causing redness and visual changes.
• Neurologic signs – peripheral neuropathy, facial nerve palsy, or CNS vasculitis (rare).

Causes and Risk Factors

GPA is an autoimmune disease; the exact trigger remains unknown, but current research points to a combination of genetic predisposition and environmental factors.

Immunologic Mechanisms

• ANCA antibodies – most patients have cytoplasmic anti‑neutrophil cytoplasmic antibodies (c‑ANCA) directed against proteinase 3 (PR3). These autoantibodies activate neutrophils, causing vessel wall injury.
• Genetic susceptibility – certain HLA‑DQ alleles (e.g., HLA‑DQβ1*04) increase risk, although no single gene determines disease.

Environmental Triggers

• Silica dust exposure (miners, construction workers) has been linked to higher ANCA‑associated vasculitis rates.
• Infections such as Staphylococcus aureus may provoke disease flares.

Risk Factors

• Age 40‑60 (peak incidence)
• Male sex (slightly higher prevalence)
• Smoking – worsens lung involvement and may increase relapse risk.
• Occupational silica exposure.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory tests, imaging, and often tissue biopsy.

Laboratory Studies

• ANCA testing – c‑ANCA (PR3‑ANCA) is positive in ~80–90 % of active generalized disease; p‑ANCA (MPO‑ANCA) may be seen in limited disease.
• Complete blood count (CBC) – may reveal anemia, leukocytosis.
• Renal panel – rising creatinine, reduced eGFR suggest kidney involvement.
• Urinalysis – hematuria, proteinuria, red‑cell casts.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging

• Chest X‑ray or CT scan – demonstrates nodules, cavitations, or diffuse infiltrates.
• Sinus CT – shows mucosal thickening, bony destruction, or polyps.
• Kidney ultrasound may be used to assess size but is not diagnostic.

Biopsy

Definitive diagnosis often requires tissue confirmation of necrotizing granulomatous inflammation with vasculitis. Common sites include:

• Kidney (renal biopsy) – gold standard for glomerulonephritis.
• Nasopharyngeal tissue or sinus mucosa.
• Skin lesions (if present).
• Lung biopsy – via bronchoscopy or CT‑guided core.

Diagnostic Criteria

The 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria give points for:

• c‑ANCA/PR3‑ANCA positivity.
• Histopathology showing granuloma.
• Upper and lower respiratory tract involvement.
• Kidney involvement.

A score ≥5 classifies a patient as having GPA with >90 % sensitivity and specificity (source: ACR/EULAR 2022 criteria).

Treatment Options

GPA is treatable, and modern regimens have dramatically improved survival—from <90 % mortality within the first year before the 1990s to >80 % five‑year survival today (Mayo Clinic, 2023).

Induction Therapy (Rapid disease control)

• High‑dose glucocorticoids – e.g., prednisone 1 mg/kg/day (max 60 mg) tapered over 4–6 months.
• Cyclophosphamide (IV pulse or oral) – traditional backbone; given for 3–6 months.
• Rituximab – anti‑CD20 monoclonal antibody; shown non‑inferior to cyclophosphamide for induction (RAVE trial, NEJM 2010). Preferred for younger patients, women of child‑bearing age, or those with renal impairment.
• Adjunctive plasmapheresis – considered for severe renal disease (eGFR <15 mL/min) or pulmonary hemorrhage (per 2020 KDIGO guidelines).

Maintenance Therapy (Prevent relapse)

• Aza­zathioprine 2 mg/kg/day or mycophenolate mofetil 1–1.5 g twice daily.
• Rituximab – 500 mg IV every 6 months for 2–5 years in patients with high relapse risk.
• Low‑dose glucocorticoids (≤10 mg/day) are usually continued for the first 12–18 months.

Targeted Biologic Therapies (Emerging)

• Avacopan – a C5a receptor inhibitor approved in 2021 for GPA; allows reduced steroid exposure (ADVOCATE trial, *Lancet* 2021).
• Investigational agents: complement inhibitors (e.g., eculizumab) and IL‑5 antagonists are under study.

Lifestyle & Supportive Measures

• Vaccinations (influenza, pneumococcal, COVID‑19) – essential before immunosuppression.
• Bone health: calcium, vitamin D, and bisphosphonates if on long‑term steroids.
• Smoking cessation – reduces lung complications and relapse risk.
• Psychosocial support – counseling, support groups, and patient education.

Living with Wegener’s Disease

Managing GPA is a lifelong partnership between the patient, rheumatologist, nephrologist, pulmonologist, and often ENT specialists.

Daily Management Tips

1. Medication adherence – never miss doses; use pill organizers or smartphone reminders.
2. Regular monitoring – blood work (CBC, liver/kidney function, ANCA titers) every 1–3 months during induction, then every 3–6 months.
3. Track symptoms – keep a diary of fever, cough, hematuria, or joint pain; report changes promptly.
4. Protect the kidneys – stay hydrated, avoid NSAIDs and high‑dose contrast unless necessary.
5. Skin care – use gentle soaps, moisturize, and protect ulcers from infection.
6. Exercise safely – low‑impact activities (walking, swimming) improve stamina without overtaxing joints.
7. Nutrition – a balanced diet rich in fruits, vegetables, lean protein, and limited sodium supports kidney health.

Psychological Well‑Being

Chronic illness can cause anxiety and depression. Access mental‑health services, practice stress‑reduction techniques (mindfulness, yoga), and consider peer‑support groups such as the Vasculitis Foundation.

Travel and Work

• Carry a summary of your diagnosis and medication list.
• Plan for medication storage (refrigeration for rituximab pre‑infusion samples, etc.).
• Discuss with your employer any needed accommodations (flexible schedules for labs or infusions).

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, risk reduction strategies are advisable:

• Avoid smoking – eliminates a known aggravating factor.
• Limit silica exposure – use protective masks in occupations with dust.
• Prompt treatment of infections – early antibiotics for sinus or respiratory infections may reduce immune activation.
• Vaccination – prevents infections that could trigger a flare.

Complications

If left untreated or poorly controlled, GPA can lead to permanent organ damage.

• Chronic kidney disease or end‑stage renal disease – may require dialysis or transplantation.
• Permanent lung fibrosis – causes chronic breathlessness.
• Upper airway deformities – saddle‑nose deformity, chronic sinusitis, or hearing loss.
• Vision loss – from scleritis or retinal vasculitis.
• Thromboembolic events – vasculitis‑related hypercoagulability can cause DVT/PE.
• Infections – immunosuppressive therapy predisposes to bacterial, viral, and fungal infections.
• Malignancy – long‑term cyclophosphamide increases bladder cancer risk; regular screening is recommended.

When to Seek Emergency Care

References

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org. Accessed April 2026.
2. CDC. Vasculitis: Clinical Information. https://www.cdc.gov. Accessed April 2026.
3. Jennette JC, et al. 2022 ACR/EULAR Classification Criteria for ANCA‑Associated Vasculitis. *Arthritis Rheumatol*. 2022;74(9):1583‑1592. DOI:10.1002/art.42071.
4. Raveendra R et al. Rituximab versus cyclophosphamide for induction of remission in GPA. *N Engl J Med*. 2010;363:221‑232.
5. Jayne D et al. Avacopan for the treatment of ANCA‑associated vasculitis. *Lancet*. 2021;398:1321‑1332.
6. KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2020 Update. https://kdigo.org.
7. Vasculitis Foundation. Patient resources and support groups. https://vasculitisfoundation.org.

```